Former Obvious Ventures GP Nan Li is referring to it as the “paradigm shift”—a new phase of the biotechnology industry where machine learning is intersecting with the wet lab.
“I just wouldn't shut up about how excited I was about digital life sciences,” Li says. “All of my investments in the last few years were in this category.”
